• Verovacines completes the validation of its vaccine and manufacturing platforms.
• Company to focus now on development to bring new vaccines to market quickly. Another
swine vaccine enters pipeline.
For the German vaccine specialist Verovaccines, all technological prerequisites are now in place to enter a new phase of the company’s development. During the validation phase both technology platforms have been significantly de-risked:
The Unified Vaccine Platform has been validated in vivo regarding vaccine combination,
usability with different species/indications and dose requirements.
The Unified Manufacturing Platform was intensively evaluated regarding reproducibility with various vaccine strains, yielding the concept of a “same-for-all” manufacturing platform for
K. lactis-based vaccines. In addition, the production process was scaled up to industrial scale at two independent service providers and thus also validated. These results provided a first estimate of the production costs of K. lactis-based vaccines, which are about 10- to 20-fold lower compared to benchmark technologies for a porcine vaccine.
Freeze-dried recombinant yeast as the basis for highly potent subunit vaccines. Following the validation of its new vaccine and manufacturing platforms, Verovaccines is expanding its portfolio with new mono- and combination vaccines to develop highly competitive vaccines for the market.
Managing Director Dr. Hanjo Hennemann: “We have recently completed a number of
extensive validation and risk mitigation studies on both platforms. This means that we can
now focus on developing vaccines to bring them to market rapidly. The upscaling studies have progressed to the point where we can manufacture our most advanced development
candidate in a GMP facility for reproducible production at industrial scale.” Prof. Dr. Sven-Erik Behrens, CSO, added: “We have initiated this growth phase by nominating another program for development of a second wholly owned porcine vaccine. This program has already reached the prototype stage of the vaccine with several candidates.”
Verovaccines is currently evaluating several strategic options to support the company’s
continued growth either through fundraising and/or partnering.
